{"id":"guaimesal","rwe":[{"pmid":"9653928","year":"1998","title":"Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin and guaimesal.","finding":"","journal":"Journal of chromatography. B, Biomedical sciences and applications","studyType":"Clinical Study"},{"pmid":"2663163","year":"1989","title":"Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients.","finding":"","journal":"Clinical therapeutics","studyType":"Clinical Study"},{"pmid":"6238767","year":"1984","title":"[Guaimesal capsules in the treatment of exacerbated chronic bronchitis].","finding":"","journal":"La Clinica terapeutica","studyType":"Clinical Study"},{"pmid":"6238760","year":"1984","title":"[Clinical evaluation of the therapeutic efficacy of a new antiphlogistic and mucus-regulating drug, guaimesal, in acute and chronic bronchopneumopathies].","finding":"","journal":"La Clinica terapeutica","studyType":"Clinical Study"}],"tags":[{"label":"guaimesal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["guaimesal"],"offLabel":[],"synonyms":["guaimesal"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"guaimesal","explanation":"Imagine your body's cells are like locks, and GUAIMESAL is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how GUAIMESAL works at a molecular level.","oneSentence":"GUAIMESAL is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"GUAIMESAL's exact mechanism of action is unknown, but it is believed to interact with a specific biological target to produce a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1337","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUAIMESAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:50:02.542774","biosimilars":[],"competitors":[],"genericName":"guaimesal","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008176","UNII":"K43273G1CW","INN_ID":"5366","UMLSCUI":"C0061934","ChEMBL_ID":"CHEMBL2105115","PUBCHEM_CID":"71250","MESH_SUPPLEMENTAL_RECORD_UI":"C043484"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1998 May 8","pmid":"9653928","title":"Gas chromatographic-tandem mass spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin and guaimesal.","journal":"Journal of chromatography. B, Biomedical sciences and applications"},{"date":"1989 May-Jun","pmid":"2663163","title":"Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients.","journal":"Clinical therapeutics"},{"date":"1984 Sep 30","pmid":"6238767","title":"[Guaimesal capsules in the treatment of exacerbated chronic bronchitis].","journal":"La Clinica terapeutica"},{"date":"1984 Sep 15","pmid":"6238760","title":"[Clinical evaluation of the therapeutic efficacy of a new antiphlogistic and mucus-regulating drug, guaimesal, in acute and chronic bronchopneumopathies].","journal":"La Clinica terapeutica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"GUAIMESAL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GUAIMESAL is a small molecule drug in the guaimesal class, but information on its target, approved indications, and commercial status is limited. Its mechanism of action and pharmacokinetic properties are also unknown. As a result, it is difficult to provide a comprehensive summary of GUAIMESAL's characteristics and clinical use. Further research is needed to determine its potential therapeutic applications and safety profile. Currently, there is limited information available on GUAIMESAL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}